Rachel E. Lerner

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Joel W. Neal, Suzanne E. Dahlberg, Heather A. Wakelee et al. · The Lancet Oncology · 2016 · 134 citations · Full text

Medicine, Oncology, Pharmacology +15

Effectiveness of a Brief Preventive Parenting Intervention Based in Self-Determination Theory

Wendy S. Grolnick, Madeline R. Levitt, Alessandra Caruso et al. · Journal of Child and Family Studies · 2021 · 127 citations

Education, Human Development, Preventive Medicine +11

Maternal involvement and children’s academic motivation and achievement: The roles of maternal autonomy support and children’s affect

Rachel E. Lerner, Wendy S. Grolnick · Motivation and Emotion · 2019 · 120 citations

Education, Educational Psychology, Human Development +12

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Hossein Borghaei, Filippo de Marinis, Daphne W. Dumoulin et al. · Annals of Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Pharmacology +13